Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature
Document Type
Article
Publication Date
3-29-2017
Department
Pharmacy
Abstract
Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
DOI
10.1177/1078155217701294
Publication Information
Dineen, Michael; Hansen, Elizabeth; Guancial, Elizabeth; and Sahasrabudhe, Deepak (2017). "Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature." Journal of Oncology Pharmacy Practice 24.4, 314-318.
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.
